Puissance Capital Management LP

-

Assets, Funds, Holdings

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Puissance Capital Management LP
CRD #175226
SEC #801-135328
CIK #0001658437
AUM 45.0 M (2026-01-13)
Employees 2 (50% Investors, 50% Brokers)
Phone212-878-3702
Address
Source [IAPD] [EDGAR] [Website]
Total AUM ($M)
170136102683402010201520212027
Sector Form 13F Holdings Value ($M)
Scynexis Inc 1.4
Corvus Pharmaceuticals Inc 0.2
 
 
 
 
 
 
 
 
 
Holdings by Sector ($M)
2502001501005002018201920202021
Type Form D Funds Date Sold AUM
HF PCM AI Opportunities Fund [2019-03-14] 1.0 M 12.0 M
Filed 2025-10-27 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
PE Puissance Cross-Border Opportunities III LLC 2018-01-25 3.0 M
PE Puissance Cross-Border Opportunities II LLC 2018-01-25 8.3 M
PE Puissance Cross-Border Opportunities IV LLC 2018-01-25 2.0 M
PE Puissance Cross Border Opportunities V LLC 2018-01-25 0.2 M
PE Puissance Life Science Opportunities Fund VII 2018-01-25 0.0 M
HF Puissance China Market Neutral Master Fund LP [2017-03-30] 44.8 M 1.9 M
Filed 2016-03-31 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
PE Puissance Cross-Border Opportunities I LP 2017-03-30 31.2 M
HF Puissance Asia Master Fund LP [2015-07-09] 10.0 M 8.5 M
Filed 2015-06-02 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $1,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
HF Puissance Capital Master Fund LP [2015-07-09] 44.8 M 80.7 M
Filed 2016-03-31 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
View All
AUM Breakdown Accounts AUM ($M)
By Client Type
(a) Individuals (other than high net worth individuals) 0 0.0
(b) Individuals (high net worth individuals) 0 33.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 1 12.0
(g) Pension and profit sharing plans 0 0.0
(h) Charitable organizations 0 0.0
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.0
(m) Corporations or other businesses not listed above 0 0.0
(n) Other 0 0.0
Total 3 45.0
By Discretionary
Discretionary 3 45.0
Non-Discretionary 0 0.0
Total 3 45.0
By Non-United States Persons
Non-United States Persons 45.0
United States Persons 0.0
Total 3 45.0
Form D Directors Role # Filings # Firms 2011 - 2026
Ted Wang Director, Executive Officer 19 3
Puissance Capital Fund GP LLC Executive Officer 2 1
Puissance Capital Management LP Executive Officer 2 1
Hanchen Jin Director 1 1
EDGAR Form CIK 2011 - 2026
13F-HR [0001658437]
3 [0001658437]
4 [0001658437]
SC 13D [0001658437]
Form 13D/13G Filer Form 13D/13G Subject Filed
Puissance Capital Management LP ViewRay Inc [2017-01-25]
Firm Profile (Form ADV)
ServesInstitutional, Retail
Fund TypesHedge Fund, Private Equity
LEI254900XD1KV0Z9RJYC26
Form 3/4/5 Subject 2011 - 2026
Puissance Life Science Opportunities Fund VI
Puissance Capital Fund GP LLC
Puissance Capital Management LP
Bellerophon Therapeutics LLC
Wang Theodore T
Puissance Capital Management GP LLC
Puissance Cross-Border Opportunities II LLC
ChronoScale Holdings Corp
Puissance Cross-Border Opportunities III LLC
Puissance Cross-Border Opportunities IV LLC
Tracon Pharmaceuticals Inc
Puissance Cross-Border Opportunities V LLC
Mirax Corp
Puissance Cross-Border Opportunities I LP
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Bellerophon Therapeutics LLC BLPH
Common Stock
2023-10-13 Sell 1,076,841 $0.10 107,684
Bellerophon Therapeutics LLC BLPH
Common Stock
2023-06-07 Sell 134,421 $0.83 111,569
Bellerophon Therapeutics LLC BLPH
Common Stock
2023-05-18 Sell 560,000 $9.46 5,297,600
Bellerophon Therapeutics LLC BLPH
Common Stock
2021-06-07 Grant 8,189 $4.00 32,756
Bellerophon Therapeutics LLC BLPH
Warrants (Right to buy) · derivative
2021-04-26 Grant 380,950 $0.00
Bellerophon Therapeutics LLC BLPH
Warrants (Right to buy) · derivative
2021-04-26 Grant 304,286 $0.00
Bellerophon Therapeutics LLC BLPH
Common Stock
2021-04-26 Grant 609,231 $4.00 2,436,924
ChronoScale Holdings Corp EKSO
Common Stock
2020-07-23 Grant 7,383 $0.00
Bellerophon Therapeutics LLC BLPH
Common Stock
2020-05-21 Grant 1,153,846 $13.00 14,999,998
Bellerophon Therapeutics LLC BLPH
Common Stock
2020-04-17 Other 553,250
ChronoScale Holdings Corp EKSO
Common Stock
2020-03-02 Other 8,918,898
ChronoScale Holdings Corp EKSO
Stock Option (right to buy) · derivative
2020-01-16 Grant 136,496 $0.00
ChronoScale Holdings Corp EKSO
Common Stock
2020-01-16 Grant 19,445 $0.45 8,750
Tracon Pharmaceuticals Inc TCON
Common Stock
2019-12-09 Sell 340,134 $2.92 993,191
Tracon Pharmaceuticals Inc TCON
Common Stock
2019-12-05 Sell 43,996 $3.05 134,188
Tracon Pharmaceuticals Inc TCON
Common Stock
2018-11-29 Buy 4,326 $1.13 4,888
Tracon Pharmaceuticals Inc TCON
Common Stock
2018-11-29 Sell 4,326 $1.21 5,234
ChronoScale Holdings Corp EKSO
Common Stock
2018-08-03 Grant 19,179 $1.79 34,330
ChronoScale Holdings Corp EKSO
Employee Stock Option (right to buy) · derivative
2018-08-03 Grant 41,000 $0.00
Comparable Firms State AUM
Altai Capital Management LP
49.8 M
Income Partners Asset Management HK Limited
Hudson Park Management LLC
NY
Fortius Financial Advisors LLC
UT
Meristem Family Wealth LLC
MN
Westcliff Capital Management LLC
CA
Schmidt Advisory Services Inc
IL
Summit Capital Management LLC
WA
BRS Financial LLC
AR
Kitano Capital LLC
TX
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com